ALS Therapy Development Institute And Oxford BioMedica Begin Second Phase Of Collaboration To Develop Gene Therapies For ALS, UK

The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase...
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.